85 results about "Albumin solution" patented technology

A compact medical device for tissue welding is provided. The hand-held plasma heads are configured for deep cuts and long cuts. A bio-compatible liquid capable of solidifying in response to application of plasma, such as an albumin solution, is applied to the wound. Plasma created from a gas such as helium is then applied to said bio-compatible liquid to solidify it and seal the wound. An additional polymerizing gas may also be applied. A feedback mechanism may maintain the temperature of said plasma. A wiper fort removal of excess liquid may also be provided.

The present invention provides a plastic container containing albumin solution and a packaged plastic container containing an albumin solution. The plastic container containing an albumin solution having an albumin concentration of 1 to 500 mg / ml, has at least one inlet / outlet for a liquid, and has a water vapor permeability of 1.5 g / m2 / day.1013.25 hPa or less when the vapor permeability is measured at a pressure of 1013.25 hPa per surface area of 1 m2 for 24 hours at a temperature of 25° C. and at a relative humidity of 60%. The plastic container containing an albumin solution can be packaged with an outer packaging material to provide the packaged plastic container.

Nanoparticles as described herein are configured to bind to bacterial contaminants, such as Gram positive bacteria, Gram negative bacteria, and endotoxins. The nanoparticles include a core comprising a magnetic material; and a plurality of ligands attached to the core. The ligands include, for example, bis(dipicolylamine) (“DPA”) coordinated with a metal ion, e.g., Zn2+ or Cu2+, to form, e.g., bis-Zn-DPA or bis-Cu-DPA, which can bind to the bacterial contaminants. The nanoparticles can be included in compositions for use in methods and systems to separate bacterial contaminants from liquids, such as liquids, such as blood, e.g., whole or diluted blood, buffer solutions, albumin solutions, beverages for human and / or animal consumption, e.g., drinking water, liquid medications for humans and / or animals, or other liquids.

The invention relates to a serum-free medium and a preparation method thereof. The preparation method of the serum-free medium includes: loading fatty acid on FAF (fatty-acid-free) albumin, and then adding an obtained albumin solution into a basic culture medium. The serum-free medium obtained by using the preparation method of the serum-free medium is stable in component and good in functional consistency, and no difference can be caused due to difference of species origins or processing batches of the albumin.

The invention discloses a fluorescence immunochromatographic kit for quantitative joint detection of four urinary micro proteins and a preparation method thereof, which solves the problems that the detection of urinary micro proteins in clinical detection cannot be simultaneously carried out. A fluorescence immunochromatographic kit for quantitative joint detection of four urinary micro proteins comprises an immunochromatographic strip coated with an albumin capture antibody, an alpha 1-microglobulin capture antibody, a transferrin capture antibody, a beta 2-microglobulin capture antibody anda protein A, and a fluorescent microsphere labeled antigen solution including a fluorescent microsphere labeled albumin solution, a fluorescent microsphere labeled alpha 1-microglobulin solution, a fluorescent microsphere labeled transferrin solution and a fluorescent microsphere labeled beta 2-microglobulin solution; and fluorescent microspheres are also labeled with IgG immunoglobulin. The invention has the advantages of rapid detection and the like.

The invention belongs to the technical field of biomedical engineering nano medicaments and discloses a preparation method of a novel albumin nano medicament under a mild condition of 37 DEG C. The preparation method comprises the following steps of: 1) preparing an albumin aqueous solution; 2) preparing a reducing agent solution, adding the reducing agent solution into the albumin aqueous solution, adding a protein denaturing agent solution, and reacting for 0.5-6 hours at the temperature of between 30 and 80 DEG C to obtain a reduced albumin solution; 3) dialyzing or ultra-filtering the reduced albumin solution, and removing unreacted reducing agent and protein denaturing agent to obtain a reduced albumin nano solution; 4) mixing the reduced albumin nano solution with an acidic buffer solution to enable the pH value to be between 2.8 and 5.0, placing the mixture in an environment of 37 DEG C, stirring to obtain albumin nano particles, dialyzing, and freeze-drying to obtain the finalalbumin nano medicament. The albumin nanoparticles have very good serum stability and storage stability, stably exists in a body circulation system, increases the half-life of the medicament, and havereduction sensitivity characteristics.

This invention provides albumin preparations with safety and without any risk of side effects, which are free from viruses or contaminating proteins and can be stably stored over a long time while showing neither changes in appearance nor decrease in content. <??>There are provided a stabilized albumin preparation produced by uniformly mixing a medium-chain fatty acid or a salt thereof and a sulfur-containing amino acid or a derivative thereof with an aqueous albumin solution (e.g., a buffer such as phosphate buffer which can be administered as pharmaceutical preparations, injection water, or a physiological saline) and dissolving them therein, and then processing the mixture solution into a formulation suitable for parenteral administration such as an intravenous fluid preparation or an injectable solution, and a stabilization method for an albumin preparation.

The invention concerns a method for producing an aqueous albumin solution from a starting albumin solution which contains stabilizer molecules which are capable of occupying binding sites of the albumin, wherein in a method for increasing the albumin binding capacity (ABiC) for other molecules, at least a portion of the stabilizer molecules is removed from the albumin of the starting albumin solution and separated from the starting albumin solution. To carry out such a method, by means of which a stabilized commercial starting albumin solution can be prepared in a manner which is simpler, faster, cheaper and in a manner which is gently on the albumin by removing the majority of the stabilizers and increasing the albumin binding capacity, the method comprises steps in which the starting albumin solution is brought into contact with a solid adsorption material the affinity of which for at least a portion, preferably all of the stabilizer molecules is higher than the affinity of the albumin for the corresponding stabilizer molecules, and the albumin is separated from the adsorption material; wherein the method is carried out at a pH of >3.

The invention discloses a preparation method of an As2O3 albumin nano medicine. The preparation method includes the following steps: 1) dissolving As2O3 powder in a NaOH solution and regulating the pH with diluted hydrochloric acid to prepare an As2O3 solution for drug supporting of albumin in later use, dissolving human serum albumin marked by folic acid molecules in a Dulbecco's phosphate buffer liquid without calcium and magnesium ions to obtain a human serum albumin solution, and adding a disulfide bond reducing agent to the human serum albumin solution and performing a reaction in a water bath pot with gentle stirring to obtain the albumin solution treated by the disulfide bond reducing agent; 2) adding the As2O3 solution to the albumin solution treated by the disulfide bond reducing agent, and stirring the mixture at room temperature to obtain an As2O3 albumin mixed solution; and 3) dialyzing the As2O3 albumin mixed solution in a dialysis bag at low temperature with a D-PBS solution to remove residual As2O3, disulfide bond reducing agent and side products thereof to obtain the As2O3 albumin nano medicine.

This invention provides albumin preparations with safety and without any risk of side effects, which are free from viruses or contaminating proteins and can be stably stored over a long time while showing neither changes in appearance nor decrease in content.There are provided a stabilized albumin preparation produced by uniformly mixing a medium-chain fatty acid or a salt thereof and a sulfur-containing amino acid or a derivative thereof with an aqueous albumin solution (e.g., a buffer such as phosphate buffer which can be administered as pharmaceutical preparations, injection water, or a physiological saline) and dissolving them therein, and then processing the mixture solution into a formulation suitable for parenteral administration such as an intravenous fluid preparation or an injectable solution, and a stabilization method for an albumin preparation.

The present invention provides a plastic container containing albumin solution and a packaged plastic container containing an albumin solution. The plastic container containing an albumin solution having an albumin concentration of 1 to 500 mg / ml, has at least one inlet / outlet for a liquid, and has a water vapor permeability of 1.5 g / m<2> / day.1013.25 hPa or less when the vapor permeability is measured at a pressure of 1013.25 hPa per surface area of 1 m<2 >for 24 hours at a temperature of 25° C. and at a relative humidity of 60%. The plastic container containing an albumin solution can be packaged with an outer packaging material to provide the packaged plastic container.

The invention provides a composition for regulating enteric microorganisms. The composition comprises solvent and components, such as, by weight, 50-500ng / mL of stem cell growth factor, 500-5000 U / mL of human interferon-Lambda, 500-5000 U / mL of human interleukin 2, 50-1000 U / mL of human interleukin 11, 1-10 mu g / mL of folium artemisiae argyi extractive, and 1vol%-3vol% of human plasma albumin solution. Through synergistic effect of the stem cell growth factor, the human interferon-Lambda, the human interleukin 2, the human interleukin 11, the human plasma albumin solution and the folium artemisiae argyi extractive, the composition can improve the whole immune system of a human body and strengthen the killing and removing ability of own immune cell to harmful flora; meanwhile, the composition can effectively regulate the intestinal microflora, increase probiotics, reduce harmful bacteria, and maintain a healthy environment of the whole intestinal canal.

The invention provides a thymidylate synthase preparation loaded albumin nano-microsphere. The nano-microsphere is prepared by the following steps: adding a solution of a thymidylate synthase preparation and an organic solvent into an albumin solution to develop and self-assemble the albumin to form a nano-microsphere; coating the thymidylate synthase preparation in the albumin nano-microsphere to form the thymidylate synthase preparation loaded albumin nano-microsphere, wherein the diameter of the albumin nano-microsphere is 40-500nm, and the thymidylate synthase preparation is 7-20 percent by mass of the albumin nano-microsphere. The nano-microsphere has the advantages of excellent biocompatibility, simple preparation process and stable physiochemical property, is capable of improving the drug stability, has a certain sustained release effect, and has potential application of clinical cancer treatment. The invention further discloses a preparation method of the thymidylate synthase preparation loaded albumin nano-microsphere.

The invention belongs to the field of solid beverages in a dry composition. The invention provides a preparation method of a composite curcumin-myofibrillar protein solid beverage. High pressure microfluidization treatment is adopted in the extraction of myofibrillar protein in chicken; during the reaction between myofibrillar protein and curcumin, pH value is firstly raised and then lowered to promote the combination of curcumin and myofibrillar protein; and finally through ultra-high pressure cold sterilization and freeze-drying, the composite curcumin-myofibrillar protein solid beverage isprepared. The invention also provides a redissolution method for redissolving the solid beverage by the use of water or an ovalbumin solution at the concentration of 4% according to a certain ratio. The solid beverage myofibrillar protein-curcumin compound prepared by the invention has high utilization rate and high nutritional value. In the solid beverage solution after redissolution, the myofibrillar protein-curcumin compound has good solubility, curcumin is greatly dispersed in the solution with no layering, and absorptivity is higher. The solid beverage is especially suitable for middle-aged and elderly people as well as those who have limited chewing function or poor digestive function.